The Regeneron Pharmaceuticals company logo is seen on a building at the company's Westchester campus in Tarrytown, New York, U.S. September 17, 2020. REUTERS/Brendan McDermid

An experimental weight-loss drug developed by REGENERON PHARMACEUTICALS combined with NOVO NORDISK A/S-B's semaglutide cut muscle mass loss by 50% in a study of nearly 1,000 obesity patients.